<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34850268</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1963</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>Suppl 2</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Der Pathologe</Title><ISOAbbreviation>Pathologe</ISOAbbreviation></Journal><ArticleTitle>[Clinical, radiological, and histopathological features of pulmonary post-COVID syndrome : A&#xa0;form of autoimmune-mediated interstitial lung disease?].</ArticleTitle><Pagination><StartPage>160</StartPage><EndPage>164</EndPage><MedlinePgn>160-164</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00292-021-01024-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">About 10% of patients develop persistent symptoms after mild/moderate COVID-19. We have previously reported detection of antinuclear autoantibodies/extractable nuclear antigens (ANA/ENA) in patients with severe COVID-19.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this small pilot study was to characterize long-/post-COVID and to evaluate possible similarities between lung involvement in long-/post-COVID and connective tissue disease (CTD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We prospectively enrolled 33&#xa0;previously healthy patients with persistent pulmonal symptoms after mild/moderate COVID-19 without hospitalization (median age, 39&#x202f;years). We performed clinical evaluation including pulmonary function tests, computed tomography (CT), and serology for ANA/ENA. In 29 of 33&#xa0;patients, transbronchial biopsies (TBBs) were taken for histopathological assessment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most patients presented with disturbed oxygen pulse in spiroergometry and slight lymphocytosis in bronchoalveolar lavage (BAL) fluid. The CT pattern showed bronchial wall thickening and increased low-attenuation volume. Autoantibodies were detected in 13 of 33&#xa0;patients (39.4%). Histopathological assessment showed interstitial lymphocytosis with alveolar fibrin and organizing pneumonia. Ultrastructural analyses revealed interstitial collagen deposition.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While histopathology of pulmonary long-/post-COVID alone is unspecific, the combination with clinical and radiological features together with detection of autoantibodies would allow for a&#xa0;diagnosis of interstitial pneumonia with autoimmune features (IPAF). Since we observe interstitial collagen deposition and since IPAF/CTD-ILD might progress to fibrosis, the persistence of autoantibodies and possible fibrotic change should be closely monitored in autoantibody-positive long-/post-COVID patients.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinestel</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Abt. XIII, Institut f&#xfc;r Pathologie und Molekularpathologie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg&#xa0;40, 89081, Ulm, Deutschland. konradsteinestel@bundeswehr.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Czech</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Abt. XIII, Institut f&#xfc;r Pathologie und Molekularpathologie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg&#xa0;40, 89081, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hackenbroch</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Abteilung Radiologie, Bundeswehrkrankenhaus Ulm, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloch</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Molekulare und zellul&#xe4;re Sportmedizin, Deutsche Sporthochschule K&#xf6;ln, K&#xf6;ln, Deutschland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagiannis</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Klinik f&#xfc;r Innere Medizin&#xa0;- Pneumologie, Bundeswehrkrankenhaus Ulm, Ulm, Deutschland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Klinische, radiologische und histopathologische Merkmale des pulmonalen Post-COVID-Syndroms : Eine Form der autoimmunvermittelten interstitiellen Lungenerkrankung?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Pathologe</MedlineTA><NlmUniqueID>8006541</NlmUniqueID><ISSNLinking>0172-8113</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText Label="ZUSAMMENFASSUNG" NlmCategory="UNASSIGNED">HINTERGRUND: Etwa 10&#x202f;% der Patienten weisen nach einer milden COVID-19-Erkrankung anhaltende Symptome auf. Wir hatten zuvor Autoantik&#xf6;rper (ANA/ENA) bei Patienten mit schweren COVID-19-Verl&#xe4;ufen erstbeschrieben.</AbstractText><AbstractText Label="FRAGESTELLUNG" NlmCategory="UNASSIGNED">Ziel dieser Pilotstudie war die Charakterisierung der Long&#x2011;/Post-COVID-Erkrankung und der Vergleich mit einer Lungenbeteiligung bei Erkrankungen aus dem rheumatischen Formenkreis (CTD-ILD).</AbstractText><AbstractText Label="METHODEN" NlmCategory="METHODS">Wir rekrutierten prospektiv 33&#xa0;Patienten mit anhaltender pulmonaler Symptomatik nach einer mild/moderat verlaufenen COVID-19-Erkrankung (Altersmedian 39&#xa0;Jahre). Wir f&#xfc;hrten Lungenfunktionstests, Computertomografien (CT) und einen serologischen Autoantik&#xf6;rpernachweis durch und entnahmen bei 29 von 33&#xa0;Patienten transbronchiale Lungenbiopsien.</AbstractText><AbstractText Label="ERGEBNISSE" NlmCategory="UNASSIGNED">Die meisten Patienten wiesen gest&#xf6;rten Sauerstoffpuls in der Spiroergometrie und eine leichte Lymphozytose in der bronchoalveol&#xe4;ren Lavage auf. In der CT zeigten sich verdickte Atemwege und ein erh&#xf6;htes Low-attenuation-Volumen. Autoantik&#xf6;rper konnten bei 13 von 33&#xa0;Patienten nachgewiesen werden (39,4&#x202f;%). Histopathologisch zeigte sich interstitielle Lymphozytose mit alveol&#xe4;rer Fibrinausf&#xe4;llung und organisierender Pneumonie. Ultrastrukturelle Analysen zeigten interstitielle Kollagenablagerung.</AbstractText><AbstractText Label="DISKUSSION" NlmCategory="CONCLUSIONS">W&#xe4;hrend die histopathologischen Befunde der Long&#x2011;/Post-COVID-Erkrankung f&#xfc;r sich alleine unspezifisch sind, w&#xfc;rde die Kombination mit klinischen und radiologischen Eigenschaften die Diagnosekriterien einer &#x201e;interstitiellen Pneumonie mit autoimmunen Merkmalen&#x201c; (IPAF) erf&#xfc;llen. Da sich interstitielle Kollagenablagerung zeigte und die IPAF/CTD-ILD einen fibrosierenden Verlauf nehmen kann, sollte eine m&#xf6;gliche Persistenz von Autoantik&#xf6;rpern und die Entwicklung fibrotischer Lungenver&#xe4;nderungen bei Long&#x2011;/Post-COVID-Patienten engmaschig kontrolliert werden.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Fibrosis</Keyword><Keyword MajorTopicYN="N">ILD</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV&#x2011;2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>1</Day><Hour>7</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34850268</ArticleId><ArticleId IdType="pmc">PMC8631553</ArticleId><ArticleId IdType="doi">10.1007/s00292-021-01024-6</ArticleId><ArticleId IdType="pii">10.1007/s00292-021-01024-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gagiannis D, Steinestel J, Hackenbroch C, Schreiner B, Hannemann M, Bloch W, Umathum VG, Gebauer N, Rother C, Stahl M. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD) Front Immunol. 2020;11:2600. doi: 10.3389/fimmu.2020.587517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587517</ArticleId><ArticleId IdType="pmc">PMC7566417</ArticleId><ArticleId IdType="pubmed">33123171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi: 10.1016/S2213-2600(21)00031-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00031-X</ArticleId><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinkmann F, M&#xfc;ller M, Reif A, Kahn N, Kreuter M, Trudzinski F, Eichinger M, Heussel C&#x2011;P, Herth FJ. Residual symptoms and lower lung function in patients recovering from SARS-CoV&#x2011;2 infection. Eur Respir. J. 2021 doi: 10.1183/13993003.03002-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03002-2020</ArticleId><ArticleId IdType="pmc">PMC7821834</ArticleId><ArticleId IdType="pubmed">33479105</ArticleId></ArticleIdList></Reference><Reference><Citation>Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, Preston R, Thillai M, Dewar A, Molyneaux PL. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Annals ATS. 2021;18(5):799&#x2013;806. doi: 10.1513/AnnalsATS.202008-1002OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202008-1002OC</ArticleId><ArticleId IdType="pmc">PMC8086530</ArticleId><ArticleId IdType="pubmed">33433263</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, Tzioufas AG. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661&#x2013;1663. doi: 10.1136/annrheumdis-2020-218009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii H, Tsuji T, Yuba T, Tanaka S, Suga Y, Matsuyama A, Omura A, Shiotsu S, Takumi C, Ono S. High levels of anti-SSA/Ro antibodies in COVID-19&#xa0;patients with severe respiratory failure: a&#xa0;case-based review. Baillieres Clin Rheumatol. 2020 doi: 10.1007/s10067-020-05359-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05359-y</ArticleId><ArticleId IdType="pmc">PMC7447083</ArticleId><ArticleId IdType="pubmed">32844364</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, Ley AM, Kyu S, Howell JC, Ozturk T. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020 doi: 10.1038/s41590-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JL, Villacreses R, Nagpal P, Guo J, Pezzulo AA, Thurman AL, Hamzeh NY, Blount RJ, Fortis S, Hoffman EA, Zabner J, Comellas AP. Small airways disease is a&#xa0;post-acute sequelae of SARS-CoV-2 infection. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270680</ArticleId><ArticleId IdType="pubmed">35289657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhadelia N, Belkina AC, Olson A, Winters T, Urick P, Lin N, Rifkin I, Kataria Y, Yuen RR, Sagar M, Snyder-Cappione JE. Distinct autoimmune antibody signatures between hospitalized acute COVID-19 patients, SARS-CoV-2 convalescent individuals, and unexposed pre-pandemic controls. 2021.</Citation></Reference><Reference><Citation>Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, Du Bois RM, Lee JS, Leslie KO, Lynch DA, Matteson EL. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976&#x2013;987. doi: 10.1183/13993003.00150-2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00150-2015</ArticleId><ArticleId IdType="pubmed">26160873</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>